XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Schedule of reconciliation of cash, cash equivalents and restricted cash
   September 30, 2022   December 31, 2021   September 30, 2021   December 31, 2020 
Cash and cash equivalents  $10,275,654   $36,080,392   $25,352,337   $13,360,463 
Restricted cash   419,495    551,794    549,730    746,792 
Total cash and cash equivalents and restricted cash in the condensed consolidated statements of cash flows  $10,695,149   $36,632,186   $25,902,067   $14,107,255 

 

Schedule of inventories
   September 30, 2022   December 31, 2021 
Raw materials and supplies  $841,859   $866,963 
Work-in-process   47,999    100,801 
Finished goods   2,496,811    3,744,029 
Total  $3,386,669   $4,711,793 

 

Schedule of finite-lived and indefinite-lived intangible assets
         

September 30, 2022

  

December 31, 2021

 
   Subsidiary  Cost  

Accumulated

Amortization

   Effect of Foreign Exchange Rates   Net Balance  

Accumulated

Amortization

   Effect of Foreign Exchange Rates   Net Balance 
Trademarks and tradenames  Curetis  $1,768,000   $(389,676)  $(209,308)  $1,169,016   $(316,930)  $43,015   $1,494,085 
Distributor relationships  Curetis   2,362,000    (347,069)   (279,628)   1,735,303    (282,277)   57,465    2,137,188 
A50 - Developed technology  Curetis   349,000    (109,899)   (41,317)   197,784    (89,384)   8,492    268,108 
Ares - Developed technology  Ares Genetics   5,333,000    (839,567)   (631,354)   3,862,079    (682,833)   129,745    4,779,912 

A30 – Acquired in-process research & development

  Curetis   5,706,000    
—  
    (669,146)   5,036,854    
—  
    144,916    5,850,916 
      $15,518,000   $(1,686,211)  $(1,830,755)  $12,001,036   $(1,371,424)  $383,633   $14,530,209 

 

Schedule of estimated useful lives of identifiable intangible assets
    Estimated Useful Life  
Trademarks and tradenames   10 years  
Customer/distributor relationships   15 years  
A50 – Developed technology   7 years  
Ares – Developed technology   14 years  
A30 – Acquired in-process research & development   Indefinite  

 

Schedule of expected amortization of intangible assets
Year Ending December 31,        
2022 (Three months)   $ 168,621  
2023     674,484  
2024     674,484  
2025     674,484  
2026     674,484  
2027     641,480  
Thereafter     3,456,145  
Total   $ 6,964,182  

Schedule of changes in carrying amount of goodwill
Balance as of December 31, 2021   $ 7,453,007  
Changes in currency translation     (477,487 )
Goodwill impairment     (6,975,520 )
Balance as of September 30, 2022   $